What is the clinical evidence from this study?

Study design: Systematic Review. Population: Cardiovascular disease and heart failure (n=3523). Intervention: Coenzyme Q10 (Ubiquinone) vs. Reduced Coenzyme Q10 (Ubiquinol) or Placebo. Primary outcome: Cardiovascular mortality.

What does this research mean for the field?

Coenzyme Q10 (ubiquinone) supplementation reduces cardiovascular mortality in heart failure patients at lower doses, whereas ubiquinol (CoQH2) does not demonstrate equivalent cardiovascular mortality benefits. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 16, 2023Current Cardiology ReportsOpen Access

Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality

View Full Paper

Ask AI

Bookmark

Key result

Coenzyme Q10 reduces cardiovascular mortality in heart failure, while ubiquinol shows no benefit.

n=3,523

Why the study?

Recent research showed beneficial effects of Coenzyme Q10 supplementation in heart failure but did not distinguish between oxidised CoQ10 and reduced CoQH2 forms.

Does Coenzyme Q10 (ubiquinone) or reduced Coenzyme Q10 (ubiquinol) supplementation reduce cardiovascular mortality in patients with heart failure?

Study Design

Type

Systematic Review (n=3,523)

Structured PICO

Does Coenzyme Q10 (ubiquinone) or reduced Coenzyme Q10 (ubiquinol) supplementation reduce cardiovascular mortality in patients with heart failure?

Population

A systematic review of 28 randomized controlled trials including 3,523 patients evaluating the efficacy of CoQ10 versus CoQH2 supplementation in preventing cardiovascular disease and reducing mortality.

Intervention

Coenzyme Q10 (ubiquinone) and reduced Coenzyme Q10 (ubiquinol) supplementation

Outcome

Cardiovascular disease prevention and cardiovascular mortality reductionhard clinical

Coenzyme Q10 (ubiquinone) is recommended over reduced Coenzyme Q10 (ubiquinol) for the treatment and prevention of cardiovascular disease in patients with heart failure due to its proven mortality benefits.

Limitations

The number of clinical trials for CoQH2 is limited.
Most CoQH2 studies used much higher concentrations than CoQ10 studies.
Lack of direct comparative clinical trials between CoQ10 and CoQH2.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May warrant form-specific CoQ10 trials in HF; leaves open which redox state drives benefit.

Cite This Study

Fladerer-Grollitsch et al. (2023) conducted a systematic review in Cardiovascular disease and heart failure (n=3,523). Coenzyme Q10 (Ubiquinone) vs. Reduced Coenzyme Q10 (Ubiquinol) or Placebo was evaluated on Cardiovascular mortality. Coenzyme Q10 supplementation reduced cardiovascular death in patients with heart failure, whereas ubiquinol did not demonstrate this benefit despite being tested at higher concentrations.

synapsesocial.com/papers/6ab781fed08471da74976b26 https://doi.org/10.1007/s11886-023-01992-6

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality

Study Design

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Topics

Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality

Study Design

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider